 |
You must be logged in to post comments on this site - please either log in or if you are not registered click here to signup
Hi you all positive people with positive minds, I'm new to this, come somebody show me some luuuv. Single balck woman, living in South Afirca and looking for some daddy.
anyone in greenbelt md
I need a sweet girl:)
HAPPY GAY MAY DAY
Hey every body, how is the weekend going?? 
REMEMBER to go to your Caucus and make your preference known.
After getting three under-the-skin injections of the tailor-made vaccine, the amount of HIV in the patients' blood (called the viral load) dropped by 80%. After a year, eight of the 18 patients still had a 90% drop in HIV levels. All patients' T-cell counts stopped dropping.
Wei Lu, Jean-Marie Andrieu, and colleagues at the University of Paris in France and Pernambuco Federal University in Recife, Brazil, tested the vaccine on 18 Brazilian patients. All had HIV infection for at least a year. Their T-cell counts -- a crucial measure of AIDS progression -- were dropping, meaning their disease was worsening. None was taking anti-HIV medications.
HIV infection normally turns these important immune system responses off. But animal studies show that when dendritic cells are "loaded" with whole, killed AIDS viruses, they can trigger effective immune responses that keep infected animals from dying of AIDS.
Nov. 29, 2004 -- It worked in mice. It worked in monkeys. And now in humans, a therapeutic vaccine has stopped HIV in its tracks.
The vaccine is made from a patient's own dendritic cells and HIV isolated from the patient's own blood. Dendritic cells are crucial to the immune response. They grab foreign bodies in the blood and present them to other immune cells to trigger powerful immune system responses to destroy the foreign invaders.
|
|
|
|
Welcome to LivingPositive.org
The vision is to create a One Stop News, Health, and Services Database for the HIV community. This site is completely interactive. So, as a community, we can come together and collectively help each other locate important News, Services, and Friendships.
Most of us know, or remember, the fear that a simple dental appointment can trigger. Personally, I still feel a little uneasy just getting a haircut. Many of us have gone for years without basic health care necessities simply because we fear the unknown. Let’s end that fear and at the same time support the people in our communities who have supported us.
The concept is simple and the possibilities are limitless. Read a good article; post it. Know a good doctor, dentist, pharmacist, hair stylist, or massage therapist; post it. Anything that you find important, or think someone else will find important; post it.
Together, we can make a difference.
Sincerely,
LivingPositive.org
|
|
|
Infants infected with HIV who are treated with one or two antiretroviral drugs within two months of birth are less likely to develop AIDS by their third birthdays than infants who are treated later, according to a new study conducted by researchers at Stanford’s School of Medicine and the Lucile Packard Children’s Hospital. Babies who received a cocktail of three antiretroviral drugs fared even better. The results are significant because there is still some uncertainty about potential side effects when drugs are administered at a very young age.
“There is a significant difference in the likelihood of disease progression, even though there is only about a month separating the initiation of therapy in the two groups,” said[censored]ociate Prof. of Pediatrics Yvonne Maldonado, the report’s senior author.
Currently, deciding when to begin treating an HIV-infected infant is the responsibility of the child’s physician, largely because the long-term effects of ongoing retroviral treatment are unknown.
“The whole idea of the study is to follow children with HIV over time and make sure we could track the illness in children, then to use that tracking to make sure we could treat children better and more effectively,” Maldonado said.
Without treatment, about 20 to 30 percent of infected infants will develop AIDS by the time they reach four months old. The rest will develop advanced symptoms by the time they are six years old.
Since some of these infected infants will appear healthy, researchers suggest that early treatment might be appropriate for even those who do not show symptoms of the disease. However, they caution that clinical trials are needed to determine if every infected newborn should be treated or if some infants will benefit more than others.
Maldonado and her colleagues collected data from hospitals throughout northern California over a 17-year period beginning in 1988. They followed the children for the first three years of life, tracked their age when AIDS developed and the rate of survival through their third birthdays.
“We were able to analyze children with the full-spectrum of disease across many years, rather than using mathematical models to predict the development of illness in the children,” Maldonado said. “We were able to see the real distribution of illness, what kinds of treatment the children were given and the ages when they started treatment.”
The researchers divided the newborns into three groups: those born between 1988 and 1991, between 1992 and 1995 and between 1996 and 2001 based on the types of therapy available in those years. Members of the early group were tested for infection by their first birthday; members of the middle and late groups were[censored]essed within the first month, and those in the late group benefited from the introduction of a special type of antiretroviral drug called a protease inhibitor, which interferes with the virus’ ability to replicate.
Not surprisingly, infants born later were more likely to receive triple-drug therapy and less likely to experience symptoms of AIDS. In fact, none of the 23 children who received triple-drug therapy developed AIDS before their third birthdays and none died.
“This is an important finding because there’s been a lot of controversy in the literature as to whether infected but asymptomatic infants should be started on therapy right away,” Maldonado said. “We’ve clearly shown that early treatment of asymptomatic infants — no matter what it is — makes a big difference in preventing or delaying the progression of the disease.”
|
|
|
Roche says to pull older HIV drug on poor demand
|
|
|
|
|
Roche Holding AG said on Wednesday it will voluntarily withdraw its anti-HIV drug Fortovase in early 2006 because demand for the drug has declined significantly.
The Swiss drugmaker said Fortovase will be discontinued in the first quarter of 2006 because of the availability of a new formulation of the drug, sold as Invirase, which is easier to tolerate.
Roche said the decision was not a result of concerns about safety or effectiveness. Roche said its drug Invirase will remain on the market.
|
|
|
|
No events for this month.
|
|
|
